Category

UF Innovate | Tech Licensing

Confronting Aids in Florida With Artificial Intelligence

A University of Florida research team is playing its part to stop the global HIV epidemic, applying the power of artificial intelligence to medical records to uncover patterns of risk and bias that have left some patients in Florida with poor access to today’s effective treatments — so effective that HIV infections are not sexually transmitted.

NCI Grant: Empowering Advanced Imaging Study to Optimize Lung Cancer Outcomes

With a $3.2 million grant from the National Cancer Institute (NCI), investigators from the newly NCI-designated UF Health Cancer Center and the University of Michigan Rogel Cancer Center will work to close evidence gaps in lung cancer care delivery. Over the five-year project, the team will examine the effectiveness of imaging surveillance strategies based on community-identified needs.

UF Health Shands Transplant Center Programs Among Nation’s Best

With patient outcomes in the nation’s top 10%, the UF Health Shands Transplant Center is once again Florida’s foremost destination for transplants. As of July 2023, five organ transplant types demonstrate exceptional results as evaluated by the Scientific Registry of Transplant Recipients, or SRTR.

UF Startups Among Companies Selected for U.S. Funding to Reduce Carbon Emissions

UF startup Micro Nano Technologies, incubating at UF Innovate | Accelerate at The Hub, is one of six companies sharing $16.2 million in funding for decarbonizing paper and forest products. The goal is to reduce net energy GHG emissions in the paper and forest products industry including increasing the share of renewable energy used, electrification, carbon capture, and energy efficiency.

EU Adds 9 Startups to Contribute Data to Copernicus Mission

The European Union (EU) has added nine startups -- including Spain-based Satlantis, the parent company of UF startup Satlantis LLC -- to contribute data to the Copernicus project. Each startup will receive a 5 million euro contract to provide additional data to Copernicus.

Kate Therapeutics Debuts With $51 Million Series A To Develop Next-Generation Genetic Medicines To Treat Muscle and Heart Diseases

Kate Therapeutics Inc., a next-generation gene therapy company, has emerged from stealth mode after securing a $51 million Series A financing round. The funding was co-led by Westlake Village BioPartners and Versant Ventures, with participation from Osage University Partners and UF Innovate | Ventures. Additionally, the company has granted Astellas Pharma Inc. an exclusive worldwide license to develop, manufacture, and commercialize KT430 for the treatment of X-linked myotubular myopathy (XLMTM).